Biopharmx Corp. (NYSEMKT: BPMX) has reported compelling topline clinical data from the Phase 2a trial of its candidate called BPX-01. The drug is being developed as a gel formulation of minocycline that is applied topically. The company said that preliminary results show that the study met its primary endpoints and that what will follow next is commencing Phase 2b study.
The Phase 2b trial will focus on evaluating the efficacy of BPX-01 in reduction of acnes. According to an earlier release, Biopharmx Corp. (NYSEMKT: BPMX) is planning to launch the next phase study of BPX-01 in July.
Observations from Phase 2a study
Biopharmx’s Phase 2a study assessed BPX-01 on 30 patients with the view of evaluating the safety, tolerability and effect on acnes. That was the first test of BPX-01 on human subjects and the topline results demonstrate compelling outcome that now pave the way for Biopharmx to continue with the development of the candidate. The company said that BPX-01 didn’t cutaneous toxicity and there were also no adverse effects. Patients who used BPX-01 in the Phase 2a study also didn’t have detectable traces of minocycline in their blood.
According to Biopharmx Corp. (NYSEMKT: BPMX)’s co-founder and president, Anja Krammer, the outcome of the Phase 2a study strongly backed the findings of the preclinical test of the candidate. Krammer added that the Phase 2a data have boosted their confidence that BPX-01 could be a revolutionary topical therapy in dealing with acne.
As Biopharmx prepares to launch Phase 2b study of BPX-01, Krammer expressed confidence that the outcome will support continued development of the candidate into a marketable product.
Does Biopharmx Corp. (NYSEMKT: BPMX) have what it takes to continue the study?
The management of Biopharmx Corp. (NYSEMKT: BPMX) has not raised the alarm over potential cash shortage. But the company’s balance sheet reflected cash and equivalents of $4 million at the end of 1Q2016. In the same quarter, the company burnt $4.5 million through operating expenses and ended up with EPS loss of $0.17, narrower than EPS loss of $0.33 in the like quarter a year ago.